Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

10/15/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Treo comp

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Acetylsalicylsyra Testmiljö

Acetylsalicylsyra

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Briggs G, Freeman RK. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 10th ed; 2015.

  2. Keim SA, Klebanoff MA. Aspirin use and miscarriage risk. Epidemiology 2006;17:435-9.

  3. Norgard B, Puho E, Czeizel AE, Skriver MV, Sorensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol 2005;192:922-3.

  4. Abe K, Honein MA, Moore CA. Maternal febrile illness, medication use, and the risk of congenital renal anomalies. Birth Defets Research Part A 2003;67:911-8.

  5. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol 2003;68:70-84.

  6. Kozer E, Nikfar S, Costei A et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002;187:1623-30.

  7. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155:26-31.

  8. Torfs CP, Katz EA, Bateson TF et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92.

  9. Di Sessa TG, Moretti ML, Khoury A et al. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994;171:892-900.

  10. Uzan S, Beaufils M, Breart G et al. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991;337:1427-31.

  11. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.

  12. Richards ID. A retrospective enquiry into possible teratogenic effects of drugs in pregnancy. Adv Exp Med Biol 1972;27:441-55.

  1. Briggs G, Freeman RK. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 10th ed; 2015.
  2. Keim SA, Klebanoff MA. Aspirin use and miscarriage risk. Epidemiology 2006;17:435-9.
  3. Norgard B, Puho E, Czeizel AE, Skriver MV, Sorensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol 2005;192:922-3.
  4. Abe K, Honein MA, Moore CA. Maternal febrile illness, medication use, and the risk of congenital renal anomalies. Birth Defets Research Part A 2003;67:911-8.
  5. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol 2003;68:70-84.
  6. Kozer E, Nikfar S, Costei A et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002;187:1623-30.
  7. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155:26-31.
  8. Torfs CP, Katz EA, Bateson TF et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92.
  9. Di Sessa TG, Moretti ML, Khoury A et al. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 1994;171:892-900.
  10. Uzan S, Beaufils M, Breart G et al. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991;337:1427-31.
  11. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.
  12. Richards ID. A retrospective enquiry into possible teratogenic effects of drugs in pregnancy. Adv Exp Med Biol 1972;27:441-55.
2 2
2 2

Koffein Testmiljö

Koffein

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Chen LW, Wu Y, Neelakantan N, Chong MF, Pan A, van Dam RM. Maternal caffeine intake during pregnancy and risk of pregnancy loss: a categorical and dose-response meta-analysis of prospective studies. Public Health Nutr. 2016;19:1233-44.

  2. Wisborg K, Kesmodel U, Bech BH et al. Maternal consumption of coffee during pregnancy and stillbirth and infant death in first year of life: prospective study. BMJ 2003;326:420-2.

  3. Cnattingius S, Signorello LB, Annerén G, Clausson B, Ekbom A, Ljunger E et al. Caffeine intake and the risk of first-trimester spontaneous abortion. New Engl J Med 2000;343:1839-45.

  4. Christian MS, Brent RL. Teratogen update: Evaluation of the reproductive and developmental risks of caffeine. Teratology 2001;64:51-78.

  5. Grosso LM, Rosenberg KD, Belanger K, Saftlas AF, Leaderer B, Bracken MB. Maternal caffeine intake and intrauterine growth retardation. Epidemiology 2001;12:447-55.

  6. Sengpiel V, Elind E, Bacelis J, Nilsson S, Grove J, Myhre R et al. Maternal caffeine intake during pregnancy is associated with birth weight but not with gestational length: results from a large prospective observational cohort study. BMC Med. 2013;11(0):42.

  7. Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017;109(0):585-648.

  8. Koffein – råd till gravida och ammande 2019. Livsmedelsverket [www]. [cited 2020-03-10].

  1. Chen LW, Wu Y, Neelakantan N, Chong MF, Pan A, van Dam RM. Maternal caffeine intake during pregnancy and risk of pregnancy loss: a categorical and dose-response meta-analysis of prospective studies. Public Health Nutr. 2016;19:1233-44.
  2. Wisborg K, Kesmodel U, Bech BH et al. Maternal consumption of coffee during pregnancy and stillbirth and infant death in first year of life: prospective study. BMJ 2003;326:420-2.
  3. Cnattingius S, Signorello LB, Annerén G, Clausson B, Ekbom A, Ljunger E et al. Caffeine intake and the risk of first-trimester spontaneous abortion. New Engl J Med 2000;343:1839-45.
  4. Christian MS, Brent RL. Teratogen update: Evaluation of the reproductive and developmental risks of caffeine. Teratology 2001;64:51-78.
  5. Grosso LM, Rosenberg KD, Belanger K, Saftlas AF, Leaderer B, Bracken MB. Maternal caffeine intake and intrauterine growth retardation. Epidemiology 2001;12:447-55.
  6. Sengpiel V, Elind E, Bacelis J, Nilsson S, Grove J, Myhre R et al. Maternal caffeine intake during pregnancy is associated with birth weight but not with gestational length: results from a large prospective observational cohort study. BMC Med. 2013;11(0):42.
  7. Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017;109(0):585-648.
  8. Koffein – råd till gravida och ammande 2019. Livsmedelsverket [www]. [cited 2020-03-10].
2 2
2 2

Kodein Testmiljö

Kodein

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet 2011;204:314.

  2. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.

  3. Nezvalová-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67:1253-61.

  4. Wurst KE, Zedler BK, Joyce AR, Sasinowski M, Murrelle EL. A Swedish Population-based Study of Adverse Birth Outcomes among Pregnant Women Treated with Buprenorphine or Methadone: Preliminary Findings. Subst Abuse. 2016;10:89-97.

  5. Bowie AC, Werler MM, Velez MP, Li W, Camden A, Guttmann A et al. Prescribed opioid analgesics in early pregnancy and the risk of congenital anomalies: a population-based cohort study. CMAJ. 2022;194(5):E152-E162.

  6. Wang X, Wang Y, Tang B, Feng X. Opioid exposure during pregnancy and the risk of congenital malformation: a meta-analysis of cohort studies. BMC Pregnancy Childbirth. 2022;22(1):401.

  7. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320-31.

  8. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69-78.

  9. Gaalema DE, Scott TL, Heil SH, Coyle MG, Kaltenbach K, Badger GJ et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction. 2012;107 Suppl 1:53-62.

  10. Sharpe C, Kuschel C. Outcomes of infants born to mothers receiving methadone for pain management in pregnancy. Arch Dis Childh 2004;89:F33-F36.

  11. Finnegan LP. Pathophysiological and behavioural effects of the transplacental transfer of narcotic drugs to the foetuses and neonates of narcotic-dependent mothers. Bull Narc 1979;31:1-58.

  12. Bunikowski R, Grimmer I, Heiser A et al. Neurodevelopmental outcome after prenatal exposure to opiates. Eur J Pediatr 1998;157:724-30.

  1. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet 2011;204:314.
  2. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.
  3. Nezvalová-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67:1253-61.
  4. Wurst KE, Zedler BK, Joyce AR, Sasinowski M, Murrelle EL. A Swedish Population-based Study of Adverse Birth Outcomes among Pregnant Women Treated with Buprenorphine or Methadone: Preliminary Findings. Subst Abuse. 2016;10:89-97.
  5. Bowie AC, Werler MM, Velez MP, Li W, Camden A, Guttmann A et al. Prescribed opioid analgesics in early pregnancy and the risk of congenital anomalies: a population-based cohort study. CMAJ. 2022;194(5):E152-E162.
  6. Wang X, Wang Y, Tang B, Feng X. Opioid exposure during pregnancy and the risk of congenital malformation: a meta-analysis of cohort studies. BMC Pregnancy Childbirth. 2022;22(1):401.
  7. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320-31.
  8. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69-78.
  9. Gaalema DE, Scott TL, Heil SH, Coyle MG, Kaltenbach K, Badger GJ et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction. 2012;107 Suppl 1:53-62.
  10. Sharpe C, Kuschel C. Outcomes of infants born to mothers receiving methadone for pain management in pregnancy. Arch Dis Childh 2004;89:F33-F36.
  11. Finnegan LP. Pathophysiological and behavioural effects of the transplacental transfer of narcotic drugs to the foetuses and neonates of narcotic-dependent mothers. Bull Narc 1979;31:1-58.
  12. Bunikowski R, Grimmer I, Heiser A et al. Neurodevelopmental outcome after prenatal exposure to opiates. Eur J Pediatr 1998;157:724-30.